Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 22682705)

1.

Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

Feifel D, Macdonald K, Cobb P, Minassian A.

Schizophr Res. 2012 Aug;139(1-3):207-10. doi: 10.1016/j.schres.2012.05.018. Epub 2012 Jun 8.

PMID:
22682705
2.

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.

Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL.

Schizophr Res. 2011 Oct;132(1):50-3. doi: 10.1016/j.schres.2011.07.027. Epub 2011 Aug 15.

PMID:
21840177
3.

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL.

Schizophr Res. 2013 Apr;145(1-3):110-5. doi: 10.1016/j.schres.2013.01.001. Epub 2013 Feb 13.

4.

No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia.

Fan X, Copeland PM, Liu EY, Chiang E, Freudenreich O, Goff DC, Henderson DC.

J Clin Psychopharmacol. 2011 Apr;31(2):231-4. doi: 10.1097/JCP.0b013e31820ebd0e.

PMID:
21346605
5.

Glucose effects on cognition in schizophrenia.

Stone WS, Seidman LJ, Wojcik JD, Green AI.

Schizophr Res. 2003 Jul 1;62(1-2):93-103.

PMID:
12765749
6.

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A.

Biol Psychiatry. 2010 Oct 1;68(7):678-80. doi: 10.1016/j.biopsych.2010.04.039. Epub 2010 Jul 7.

PMID:
20615494
7.

Impairment of verbal memory and learning in antipsychotic-naïve patients with first-episode schizophrenia.

Hill SK, Beers SR, Kmiec JA, Keshavan MS, Sweeney JA.

Schizophr Res. 2004 Jun 1;68(2-3):127-36.

PMID:
15099597
8.

Sex differences in verbal memory in schizophrenia patients treated with "typical" neuroleptics.

Sota TL, Heinrichs RW.

Schizophr Res. 2003 Jul 1;62(1-2):175-82.

PMID:
12765758
9.
10.

Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, Marder SR.

Schizophr Res. 2013 Jul;147(2-3):393-7. doi: 10.1016/j.schres.2013.04.023. Epub 2013 May 12.

PMID:
23676253
11.

The role of encoding strategies in the verbal memory performance in patients with schizophrenia.

Gsottschneider A, Keller Z, Pitschel-Walz G, Froböse T, Bäuml J, Jahn T.

J Neuropsychol. 2011 Mar;5(Pt 1):56-72. doi: 10.1348/174866410X497382.

PMID:
21366887
12.

A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.

Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA; Canadian Switch Study Group.

J Clin Psychopharmacol. 2003 Aug;23(4):400-4.

PMID:
12920417
13.

Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients.

Serper MR, Bergman A, Copersino ML, Chou JC, Richarme D, Cancro R.

Psychiatry Res. 2000 Feb 14;93(1):21-32.

PMID:
10699225
14.

Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.

Rémillard S, Pourcher E, Cohen H.

J Int Neuropsychol Soc. 2008 Jan;14(1):110-8.

PMID:
18078537
15.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
16.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
17.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR.

Schizophr Res. 2012 Apr;136(1-3):25-31. doi: 10.1016/j.schres.2011.11.001. Epub 2011 Dec 12.

PMID:
22169248
18.

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk SR, Marder SR, Mintz J.

Schizophr Bull. 1999;25(2):223-32.

19.

Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.

Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M.

Schizophr Res. 2008 Apr;101(1-3):320-30. doi: 10.1016/j.schres.2008.01.020. Epub 2008 Mar 5.

PMID:
18321680
20.

Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia.

Skelley SL, Goldberg TE, Egan MF, Weinberger DR, Gold JM.

Schizophr Res. 2008 Oct;105(1-3):78-85. doi: 10.1016/j.schres.2008.05.027. Epub 2008 Jul 10.

PMID:
18617370
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk